Advertisement

 

 

Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.

Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
Author Information (click to view)

Fujii K, Nakamura H, Nishimura T,


Fujii K, Nakamura H, Nishimura T, (click to view)

Fujii K, Nakamura H, Nishimura T,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Expert review of proteomics 2017 03 17() 1-14 doi 10.1080/14789450.2017.1304215
Abstract
INTRODUCTION
Lung cancer and related diseases have been one of the most common causes of deaths worldwide. Genomic-based biomarkers may hardly reflect the underlying dynamic molecular mechanism of functional protein interactions, which is the center of a disease. Recent developments in mass spectrometry (MS) have made it possible to analyze disease-relevant proteins expressed in clinical specimens by proteomic challenges. Areas covered: To understand the molecular mechanisms of lung cancer and its subtypes, chronic obstructive pulmonary disease (COPD), asthma and others, great efforts have been taken to identify numerous relevant proteins by MS-based clinical proteomic approaches. Since lung cancer is a multifactorial disease that is biologically associated with asthma and COPD among various lung diseases, this study focused on proteomic studies on biomarker discovery using various clinical specimens for lung cancer, COPD, and asthma. Expert commentary: MS-based exploratory proteomics utilizing clinical specimens, which can incorporate both experimental and bioinformatic analysis of protein-protein interaction and also can adopt proteogenomic approaches, makes it possible to reveal molecular networks that are relevant to a disease subgroup and that could differentiate between drug responders and non-responders, good and poor prognoses, drug resistance, and so on.

Submit a Comment

Your email address will not be published. Required fields are marked *

15 + 7 =

[ HIDE/SHOW ]